Curr Opin Neurol 2002 Jun;15(3):233-7
Galboiz Y, Miller A.
Division of Neuroimmunology and Multiple Sclerosis Center, Carmel Medical Center, Rappaport Institute for Research in the Medical Sciences and Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
The need to ensure an accurate diagnosis and proper treatment for multiple sclerosis patients, considering the various clinical and immunopathological subtypes of the disease, requires the identification of biomarkers that measure disease activity and predict the course of disease development in individual patients.
Moreover, the identification of effective indicators will lead not only to optimized patient treatment but also to the development of better tools for evaluating clinical trials.
Recent studies focusing on the identification of possible immunological markers in multiple sclerosis will be reviewed.